Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

January 28, 2002

Primary Completion Date

March 17, 2005

Study Completion Date

November 1, 2005

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

gefitinib

DRUG

temozolomide

Trial Locations (11)

10021

Memorial Sloan-Kettering Cancer Center, New York

15232

University of Pittsburgh Cancer Institute, Pittsburgh

53792

University of Wisconsin Comprehensive Cancer Center, Madison

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94143-0128

UCSF Comprehensive Cancer Center, San Francisco

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

75390-9154

Simmons Cancer Center - Dallas, Dallas

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

78284-6220

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00027625 - Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma | Biotech Hunter | Biotech Hunter